Silexion Therapeutics

SLXN

Market cap $1.99M

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers

Successful initiation of the Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), one of Israel's largest and most prominent academic medical centers, clears the site to commence patient screening Milestone marks the start of Silexion's transition of the SIL204 program from regulatory preparation into active clinical execution, following the Company's previously announced regulatory authorizations from the Israeli Ministry of Health and Germany's Federal Institute for Drugs and Medical Devices (BfArM) With site initiation complete, patient screening at TASMC is expected to commence in the coming weeks, with first patient dosing anticipated to follow Additional Israeli and German trial sites are progressing through activation and are expected to join the Phase 2/3 program in the coming months Grand Cayman, Cayman Islands, July 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the successful initiation of its Phase 2/3 clinical trial of SIL204, the Company's lead small interfering RNA (siRNA) product candidate, at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), formally activating the first clinical site for the study in patients with locally advanced pancreatic cancer (“LAPC”). With the trial now initiated at TASMC, the site is cleared to commence patient screening.

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate the Phase 2/3 clinical trial of SIL204 in Germany

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company's Chief Executive Officer, Ilan Hadar, and the Company's Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.  

Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in developing SIL204. Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in developing SIL204.

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,995,092 of the Company's ordinary shares originally issued in August 2025 and September 2025 having a reduced exercise price of $0.50 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-290074) and an effective resale registration statement on Form S-3 (No. 333-291210). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about May 18, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells harboring a KRAS mutation, supporting potential future evaluation alongside anti-PD-1 therapies including pembrolizumab (Keytruda®) Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells harboring a KRAS mutation, supporting potential future evaluation alongside anti-PD-1 therapies including pembrolizumab (Keytruda®)

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of excellence

CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program